{"brief_title": "An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)", "brief_summary": "The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).", "condition": ["Diabetes Mellitus, Type 2", "Chronic Renal Insufficiency"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["sitagliptin", "Placebo to Sitagliptin", "glipizide", "Placebo to glipizide"], "description": ["One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.", "One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.", "One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.", "One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations."], "arm_group_label": ["Sitagliptin", "Placebo", "Sitagliptin", "Placebo", "Sitagliptin"], "other_name": ["MK0431"], "criteria": "Inclusion Criteria: - Patients who are at least 18 years of age diagnosed with type 2 diabetes mellitus (T2DM) (a specific type of diabetes). - Patient has renal (kidney) insufficiency (inadequate kidney function) Exclusion Criteria: - Patient has had heart problems (such as a heart attack or chest pain) or stroke within the past 6 months or any condition or therapy which, in the opinion of the investigator, may not be in the patient's best interest to participate. - Pregnant or breast feeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Type 2 Diabetes Mellitus and Chronic Renal Insufficiency", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Renal Insufficiency", "Renal Insufficiency, Chronic", "Sitagliptin Phosphate", "Glipizide"], "id": "NCT00095056"}